# ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer

Source: https://onco.cc/trials/nct04662580/  
OnCo record `nct04662580` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of ARX517 alone or with apalutamide or abiraterone in metastatic prostate cancer, run by Janssen Research & Development, LLC, active but no longer recruiting.

## Summary

ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer is a phase 1 interventional study registered as NCT04662580 by Janssen Research & Development, LLC; 183 participants are planned, it started on 2021-05-03; the registry gives 2026-12-31 as its primary completion date. Interventions recorded: ARX517, Apalutamide, Abiraterone acetate, Prednisone. Conditions listed: Metastatic Prostate Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04662580
- Phase: 1
- Setting: A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer
- Sponsor: Janssen Research & Development, LLC
- Enrolled: 183

## Sources

- ClinicalTrials.gov NCT04662580: https://clinicaltrials.gov/study/NCT04662580

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Abiraterone acetate](https://onco.cc/drugs/abiraterone/), [Apalutamide](https://onco.cc/drugs/apalutamide/), [ARX517](https://onco.cc/drugs/arx517/), [Prednisone](https://onco.cc/drugs/prednisone/)
- companies: [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)

---
JSON: https://onco.cc/api/v1/entities/nct04662580.json